Morie A. Gertz, MD of Mayo Clinic discusses the standard of care options for frontline therapy of Waldenstroms Macroglobulinemia at…
Morie A. Gertz, MD of Mayo Clinic discusses the roles of proteasome inhibitors and immunomodulatory agents in Waldenstroms Macroglobulinemia at…
Morie A. Gertz, MD of Mayo Clinic discusses Ibrutinib and Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematology…
Morie A. Gertz, MD of Mayo Clinic discusses MYD88 mutation and management of Waldenstroms Macroglobulinemia at Scripps Health 36th Annual…
Morie A. Gertz, MD of Mayo Clinic discusses Panobinostat and other HDAC inhibitors in relapsed Multiple Myeloma at Scripps Health…
Morie A. Gertz, MD of Mayo Clinic discusses how Ixazomib will change therapeutic algorithms for myeloma at the Scripps Health…
Morie A. Gertz, MD of Mayo Clinic discusses elotuzumab second line or third line regimen following a Proteasome-IMiD based combination…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Morie A. Gertz, MD of Mayo Clinic discusses how Daratumumab is to be used anti-CD38 monoclonal antibody Scripps Health 36th…
Morie A. Gertz, MD of Mayo Clinic discusses the new novel agents which might have significant therapeutic impact in multiple…
Ryan Cassaday, MD, from Fred Hutchinson Cancer Research Center, Seattle, WA, discusses clinical data presented on acute lymphoblastic leukemia (ALL)…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about venetoclax (ABT-199), which…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center,…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the side-effects profile of…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the importance of…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR talks about gene expression…
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss several…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the future of…
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses how FLT3 occurs in about a third of adult AML patients…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses phase III RATIFY trial 7+3 chemo plus Midostaurin or placebo in…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses Quizartinib FLT3 inhibitor status at the Scripps 36th Annual Conference: Clinical…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the fact that no data for FLT3 inhibitor more effective than…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses IDH1 and IDH2 results in AML at the Scripps 36th Annual…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses DNMT3A and the impact on the course of AML at the…
Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the new targetable molecular abnormalities in AML at the Scripps 36th…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses how GC4419 may assist in delivering more…
Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses how GC4419 appears to decrease duration of…
Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses the trial results of Superoxide Dismotase Mimetic…
Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses the GC4419 mechanism of action at ASTRO…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Lisa Shnayder, MD of the University of Kansas Medical Center discusses how free tissue transfer can help intelligibility of speech…
Lisa Shnayder, MD of the University of Kansas Medical Center discusses the new cost saving technologies for reconstructing a mandible…
Lisa Shnayder, MD of the University of Kansas Medical Center discusses the challenges reguarding reconstructing oral cavity defects after treatment…
Lisa Shnayder, MD of the University of Kansas Medical Center high;lights that there is no clear data HPV increases risk…
Jessica M. Frakes, MD of Moffitt Cancer Center states that HPV-positive oropharyngeal cancer can be found through imaging and physical…
Jessica M. Frakes, MD of Moffitt Cancer Center discusses why NCCN guidelines may not be best management of HPV+ patients…
Thomas Churilla, MD of Fox Chase Cancer Center discusses Uninsured and Medicaid patients with head and neck cancer more likely…
Ezra Cohen, MD of the University of California at San Diego discusses new agents in clinical trials that appear interesting…
Ezra Cohen, MD of the University of California at San Diego discusses the potential role for PD-1 and PD-L1 monoclonal…
Ezra Cohen, MD of the University of California at San Diego discusses if biomarkers help select patients more or less…
Ezra Cohen, MD of the University of California at San Diego discusses role do for EGFR-TKIs in the future management…
Ezra Cohen, MD of the University of California at San Diego discusses other LUX-Head & Neck trials are ongoing at…
Ezra Cohen, MD of the University of California at San Diego discusses the results of the LUX-Head & Neck 1:…
Ezra Cohen, MD of the University of California at San Diego discusses how the EGFR monoclonal antibody, Nimotuzumab, differ from…
Ezra Cohen, MD of the University of California at San Diego discusses the importance of targeting EGFR in Squamous Cell…
Ezra Cohen, MD of the University of California at San Diego discusses the last 5 years of HPV-associated squamous cell…
Is it really important to mention treatment side effects to your healthcare team? CLL expert Dr. Nicole Lamanna of Columbia…
Dr. Michael Keating of MD Anderson and Dr. Nicole Lamanna of Columbia University give a thorough description of FISH and…
In February 2016, the FDA placed a full clinical hold on the trials for the MPN treatment pacritinib. To find…
Dr. Keith C. Bible, MD or the Mayo Clinic discusses the clinical benefit rate and duration of response for first…
Dr. Keith C. Bible, MD or the Mayo Clinic discusses how important a target is VEGFR in well-differentiated thyroid cancer…
Dr. Keith C. Bible, MD or the Mayo Clinic discusses standard of care for RAI refractory well-differentiated thyroid cancer at…
Dr. Keith C. Bible, MD or the Mayo Clinic discusses tricks to help minimize and prevent adverse events with sorafenib…
Dr. Keith C. Bible, MD or the Mayo Clinic discusses targeting genetic abnormalities and signaling pathways for papillary and follicular…
Dr. Bhisham Chera, MD of the University of North Carolina Hospitals, Chapel Hill discusses the scientific rationale behind the attempt…
Dr. Bhishamjit S. Chera, MD of University of North Carolina Hospitals, Chapel Hill, North Carolina gives an overview of a…
Dr. Bhishamjit S. Chera, MD of the University of North Carolina Hospitals, Chapel Hill, North Carolina discusses his study at…
Dr. Jose Zevallos, MD of University of North Carolina Hospitals discusses his study which notes the type and number of…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Researchers examined the molecular characteristics of OPSCC caused by HPV in an effort to determine which DNA mutations predict lower…
Dr. David Adelstein, MD of Cleveland Clinic discusses whether there is there a role for neoadjuvant chemotherapy or chemo-radiation in…
Dr. David Adelstein, MD of Cleveland Clinic discusses novel agents under investigation that might find a future role in adjuvant…
Dr. David Adelstein, MD of Cleveland Clinic discusses what are the indications for chemo-radiation in locally advanced oral cavity carcinomas…
Dr. David Adelstein, MD of Cleveland Clinic discusses what is the optimal primary therapeutic option for patients with early stage…
Dr. David Adelstein, MD of Cleveland Clinic discusses what is the role of radiation therapy in oral cavity cancers at…
Dr. David Adelstein, MD of Cleveland Clinic discusses Which systemic agents are most effective as part of a chemo-radiation regimen…
Dr. David Adelstein, MD of Cleveland Clinic discusses which groups are most susceptible to oral cavity cancers at the ASTRO…
4,042 patients were included: 2,538 (63%) received CRT. Median follow-up was 19 months. Unadjusted median OS was longer with the…
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American…
Approximately 45,000 new head and neck squamous cell carcinomas (HNSCC) are diagnosed annually in the United States, with at least…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
MPN expert Dr. Rami Komrokji of Moffitt Cancer Center discusses various genetic marker subsets of myeloproliferative neoplasms (MPNs) and how…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Anton Hagenbeek, MD, PhD, from the University of…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the side-effects of ibrutinib, based on data presented…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic…
There is an increasing spectrum of available therapies for patients with cancer, which has improved the outcomes of varied cancer…
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, summarises data on the management of patients with multiple myeloma that…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà , MD, from Sapienza University, Rome, Italy,…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of…
Jean-Jacques Kiladjian, MD, PhD from the Saint-Louis Hospital & Paris Diderot University, Paris, France provides an overview of the COMFORT-II…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA talks about the use of elotuzumab for the…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about the new therapies in multiple myeloma, such as ixazomib,…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a clinicogenetic risk…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a few new…
Patient Power founder Andrew Schorr visits with Dr. Michael Keating of MD Anderson Cancer Center to ask audience questions about…
Multiple myeloma expert Dr. Robert Orlowski responds to a question from a Patient Power community member related to access to…
Can we interrupt the fibrotic process? MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center explains PRM-151, and how…
Which CLL patients benefit most from chemotherapy? CLL expert Dr. Nicole Lamanna explains the various therapeutic agents currently in use,…
Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark talks about the Nordic Lymphoma Group (NLG) study on the…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer…
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of…
A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product.…
Claire Harrison of the Guy’s and St. Thomas Hospital in London, UK, talks about how in the UK, clinicians have…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about the molecular architecture of myeloproliferative…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of…
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH)…
Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion…
Fresh from the 2015 American Society of Hematology (ASH) conference, Dr. Michael Mauro of Memorial Sloan Kettering Cancer Center delves…
Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the…
Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: What effect will newly approved…
At a recent MPN town meeting, MPN experts Dr. Srdan Verstovsek and Dr. Naval Daver from MD Anderson Cancer Center…
Watch an in-depth discussion on emerging immunotherapy approaches for advanced prostate cancer with MD Anderson Cancer Center experts, Drs. Sumit…
Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark provides an overview of the LUMIERE clinical trial of alisertib…
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at…
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase…
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target…
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ, provides an overview of the session “Social Media for the…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Richard A. Van Etten, MD of UC Irvine Health Chao Family gives an update on Chronic Myeloid Leukemia using data…
Susan OBrien, MD of UC Irvine Health Chao Family gives an update of Chronic Lymphocytic Leukemia with data from ASH…
Kanwarpal S. Kahlon , MD of UC Irvine Health Chao Family gives an Update on Multiple Myeloma at Spotlight on…
Deepa Jeyakumar, MD of UC Irvine Health Chao Family gives an update on Acute Myeloid Leukemia at Spotlight on ASH…
Angela Fleischman, MD, PhD of University of California, Irvine discusses Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials;…
Monica El-Masry, MD & Bhavana Pathak, MD present Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies at Spotlight…
Eric Van Cutsem, MD of University of Leuven discusses the RECOURSE trial design and its primary endpoint results at ASCO…
Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer…
Eric Van Cutsem, MD of University of Leuven discusses a subgroup analysis of the RECOURSE trial and new information regarding…
Eric Van Cutsem, MD of University of Leuven discusses the TAS-102 mechanism of action and potential toxicity in advanced CRC
Eric Van Cutsem, MD of University of Leuven discusses the therapeutic algorithm for TAS-102 in metastatic colorectal cancer at ASCO…
Axel Grothey, MD of Mayo Clinic discusses the design of the RECOURSE trial on which the FDA approved TAS-102 at…
Axel Grothey, MD of Mayo Clinic discusses the performance status of patients in the RECOURSE trial at ASCCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at…
Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal…
Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment…
Axel Grothey, MD of Mayo Clinic discusses key trials that will move treatment forward in colorectal cancer at ASCO GI…
Axel Grothey, MD of Mayo Clinic discusses why more money should be allocated to early detection and screening in colorectal…
Axel Grothey, MD of Mayo Clinic discusses potential cases to use Regorafenib over TAS-102 ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas…
Alan P. Venook, MD of University of California San Francisco discusses using TAS-102 after initial therapy with regorafenib at ASCO…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain provides an overview of the SIRIUS clinical trial of…
Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain discusses the importance of identifying frail/elderly patients using well-establish…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the highlights in the field…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about biomarkers of cardiotoxicity in…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about cardio-oncology in multiple myeloma…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses mutational load of colorectal and non-colorectal cancers may benefit…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses the MAVERICC Phase II study results at ASCO GI…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor…
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at…
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 Adverse events compared to other approved flouropyrmidines at…
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in…
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from…
Alan P. Venook, MD of University of California San Francisco discusses the primary and secondary endpoints of the RECOURSE trial…
Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for…
Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib…
Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses associated with long-term therapies in chronica lymphocytic leukemia (CLL).…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies…
Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at…
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of…
Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal…
Daniel Catenacci, MD of The University of Chicago Medicine discusses the NEOSCOPE trial results and management of resectable esophageal adenocarcinoma…
Daniel Catenacci, MD of The University of Chicago Medicine discusses why the NEOSCOPE trial may not be significantly and clinically…
Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE…
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or…
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced…
The Role of PD-L1 Pathway in Cancer Immune Invasion
The Importance of PD-L1 Expressions on Tumor and Immune Cells
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London,…
Howard S Hochster, MD of Yale Medical Center discusses adverse event profile for TAS-102 at ASCO GI 2016
Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer…
Howard S Hochster, MD of Yale Medical Center discusses Phase III RECOURSE trial on which FDA approval for TAS-102 was…
Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO…
Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as…
Davendra Sohal, MD of Cleveland Clinic discusses the reason microsatellite instability responds to immunotherapy in colon cancer at ASCO GI…
Davendra Sohal, MD of Cleveland Clinic discusses Pancreatic Cancer News from ASCO GI 2016
Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016
Davendra Sohal, MD of Cleveland Clinic discusses the highlights from ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab more value in squamous cell carcinomas or…
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab looks promising according to KEYNOTE-028 results at…
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses clinical trial efforts in UGI cancers with the…
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials…
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses KEYNOTE-028 results with pembrolizuma at ASCO GI 2016
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses Checkmate-032 trial and the results presented in UGI cancers at ASCO…
Al B Benson, MD of Northwestern University explains TAS-102 at ASCO GI 2016
Al B Benson, MD of Northwestern University discusses the optimal dosage using Regorafinib in colorectal cancer at ASCO GI 2016
Al B Benson, MD of Northwestern University discusses managing patients on regorafenib including adverse events at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses T-DM1 trial results, surprising or disappointing? from ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction…
Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma…
Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without…
Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy…
Joel Randolph Hecht, MD of UCLA Health discusses antiangiogenic agents in advanced esophagogastric adenocarcinomas at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy…
Manish Shah, MD of Weill-Cornell Medical Center discusses the standard of care for good performance status patients with advanced gastric…
Manish Shah, MD of Weill-Cornell Medical Center discusses the phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma…